跳至主要内容
临床试验/NCT03063931
NCT03063931Unknown2 期

Effect of the Oral Route of Magnesium on Pre and Post-mastectomy on the Post-surgery Pain

University Hospital, Clermont-Ferrand1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2017年3月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
100
试验地点
1
主要终点
Measure of average pain intensity by a numerical rating scale

研究概览

简要总结

In breast cancer patients undergoing a mastectomy, the aim of this study is to evaluate if the magnesium administered for 6 weeks starting two weeks before the surgery induces a decrease of pain intensity one month post-mastectomy compared to the placebo group.

详细描述

This is a randomized, placebo-controlled double-blind clinical trial conducted in the Oncology Hospital, Clermont-Ferrand, France, in 100 patients suffering from breast cancer and undergoing a total mastectomy.

This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale. Cognition, anxiety, depression, sleep and quality of life are also assessed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •- Age ≥ 18 years,
  • •Patient with breast cancer who has a scheduled total mastectomy with or without treatment two weeks after inclusion with or without preoperative chemotherapy,
  • •Patient free from any new treatment or diet at the time of the inclusion,
  • •Cooperation and understanding sufficient to comply with the requirements of the study,
  • •Patients affiliated to the French Social Security,
  • •Patients with free and informed consent has been obtained

排除标准

  • •Hypersensitivity to the active substance or to any of the excipients
  • •Patient with magnesemia >1,05 mmol/l
  • •Patient with severe renal insufficiency with creatinine clearance <30 ml min,
  • •Patient with an addiction to alcohol, as determined by the investigator,
  • •Diabetes (type I and II),
  • •Medical and surgical history incompatible with the study,
  • •Patient receiving treatment with Quinidine, L-Dopa,
  • •Childbearing age, no use of effective contraceptive method, pregnancy or lactation
  • •Patient exclusion period, or the total allowable compensation exceeded
  • •Patients undergoing a measure of legal protection (guardianship, supervision ...)

研究组 & 干预措施

magnesium

Experimental

干预措施: Magnesium: Magnésium UPSA Action Continue® (Drug)

placebo

Placebo Comparator

干预措施: Placebo: Lactose (Drug)

结局指标

主要结局

Measure of average pain intensity by a numerical rating scale

时间窗: 5 days before the visit at 1 month post-mastectomy

Measure of average pain intensity by a numerical rating scale assessed 5 days before the visit at 1 month post-mastectomy in magnesium and placebo groups.

次要结局

  • Evaluation of analgesic consumption(at 3 month)
  • Cognitive assessment by Trail Making Test A and B(at month 1 and month 3)
  • Quality of life assessment by EORTC QLQ-C30(at month 1 and month 3)
  • Quality of life assessment by Pittsburg Sleep Quality Index (PSQI)(at month 1 and month 3)
  • Pain assessment by the Neuropathic pain questionnaire(at month 1 and Month 3)
  • Anxiety and Depression assessment by DASS scale(at month 1 and month 3)
  • Urine assays of magnesium(at month 1 and month 3)
  • Plasma and erythrocyte assays of magnesium(at inclusion visit, month 1 and month 3)
  • Creatinine dosage(at inclusion visit)

研究者

发起方
University Hospital, Clermont-Ferrand
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Pain and Magnesium | 临床试验